Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Rad Laboratories

234.41
+0.0000
Volume:5.00
Turnover:1.24K
Market Cap:6.57B
PE:-3.59
High:234.41
Open:234.41
Low:234.41
Close:234.41
Loading ...

RBC Capital Remains a Buy on Bio-Rad Laboratories (BIO)

TIPRANKS
·
09 Dec 2024

Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

Simply Wall St.
·
26 Nov 2024

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Insider Monkey
·
25 Nov 2024

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Business Wire
·
21 Nov 2024

Bio-Rad Laboratories Down Over 6%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
16 Nov 2024

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

Insider Monkey
·
13 Nov 2024

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.
·
02 Nov 2024

Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Simply Wall St.
·
01 Nov 2024

Bio-Rad Laboratories Is Maintained at Outperform by RBC Capital

Dow Jones
·
01 Nov 2024

UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating

MT Newswires Live
·
31 Oct 2024

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Business Wire
·
31 Oct 2024

RBC Capital Sticks to Their Buy Rating for Bio-Rad Laboratories (BIO)

TIPRANKS
·
31 Oct 2024

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...

GuruFocus.com
·
31 Oct 2024

Bio-Rad Laboratories Reports Q3 2024 Earnings Growth

TIPRANKS
·
31 Oct 2024

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Reuters
·
31 Oct 2024

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Zacks
·
31 Oct 2024

Bio-Rad Laboratories Q3 2024 Adj. EPS $2.01 Beats $1.16 Estimate, Sales $649.729M Beat $628.174M Estimate

Benzinga
·
31 Oct 2024

Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week

Simply Wall St.
·
25 Oct 2024

Bio-Rad Laboratories (BIO) Gets a Buy from RBC Capital

TIPRANKS
·
25 Oct 2024